Guardant Health, Inc. (GH)
Chart Events
Performance Outlook
| Previous Close | 43.66 |
| Open | 43.65 |
| Bid | 44.74 x 800 |
| Ask | 44.87 x 1400 |
| Day's Range | 42.01 - 45.66 |
| 52 Week Range | 27.65 - 133.82 |
| Volume | |
| Avg. Volume | 1,492,901 |
| Market Cap | 4.611B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GH
Related Research
- Guardant Health, Inc.Analyst Report: Guardant Health, Inc.Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.RatingFair ValueEconomic Moat2 months agoMorningstar
- Motley Fool
Why Shares of Guardant Health Dropped 33.6% in May
It's a bit early for investors to jump the ship regarding Guardant because the biotech stock still has plenty of good long-term prospects. The test will compete with the Galleri blood-based cancer screening by the Grail unit of Illumina and a the Cologuard fecal screening by Exact Sciences. Investors are also watching the outcome of a lawsuit, filed in March by Illumina, that claims that Guardant and two of its founders -- former employees of Illumina -- used Illumina's propriety information to help them launch Guardant.
- American City Business Journals
In cancer detection showdown, Guardant Health seeks dismissal of 'sham' Illumina lawsuit
Billions of dollars have been poured into companies seeking early detection of cancer through common blood draws.
- Simply Wall St.
Insiders who placed huge bets on Guardant Health, Inc. (NASDAQ:GH) earlier this year would be disappointed with the 49% drop
The recent price decline of 49% in Guardant Health, Inc.'s ( NASDAQ:GH ) stock may have disappointed insiders who...
